- Published: 01 October 2014
- Written by Editor
By Jon C Ogg - 24wallst.com
Tuesday brought the very unfortunate news that a confirmed case of Ebola has arrived in the United States. With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story. 24/7 Wall St. has included a few of the companies that are seeing gains from the Ebola theme.
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were up only 5.3% shortly ahead of the opening bell on 20,000 shares or so. The stock was initially up 5% at $9.78 and then was up over 10% and just above $10 in the after-hours on Tuesday, but that was after a 6.7% drop to $9.78 in regular trading. Its 52-week range is $4.55 to $14.62. J.P. Morgan gave this an Overweight rating and $20 price target on August 8.
